LL-37_Renalexin hybrid peptide exhibits antimicrobial activity at lower MICs than its counterpart single peptides
An alarming global public health and economic peril has been the emergence of antibiotic resistance resulting from clinically relevant bacteria pathogens, including Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumonia , Acinetobacter baumannii , Pseudomonas aeruginosa , and Enterobact...
Gespeichert in:
Veröffentlicht in: | Applied microbiology and biotechnology 2024-12, Vol.108 (1), p.126-126, Article 126 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | An alarming global public health and economic peril has been the emergence of antibiotic resistance resulting from clinically relevant bacteria pathogens, including
Enterococcus faecium
,
Staphylococcus aureus
,
Klebsiella pneumonia
,
Acinetobacter baumannii
,
Pseudomonas aeruginosa
, and
Enterobacter
species constantly exhibiting intrinsic and extrinsic resistance mechanisms against last-resort antibiotics like gentamycin, ciprofloxacin, tetracycline, colistin, and standard ampicillin prescription in clinical practices. The discovery and applications of antimicrobial peptides (AMPs) with antibacterial properties have been considered and proven as alternative antimicrobial agents to antibiotics. In this study, we have designed, produced, and purified a recombinant novel multifunctional hybrid antimicrobial peptide LL-37_Renalexin for the first time via the application of newly designed flexible GS peptide linker coupled with the use of our previously characterized small metal-binding proteins SmbP and CusF3H+ as carrier proteins that allow for an enhanced bacterial expression, using BL21(DE3) and SHuffle T7(DE3)
Escherichia coli
strains, and purification of the hybrid peptide via immobilized metal affinity chromatography. The purified tag-free LL-37_Renalexin hybrid peptide exhibited above 85% reduction in bacteria colony-forming units and broad-spectrum antimicrobial effects against
Staphylococcus aureus
,
Escherichia coli
, Methicillin-resistant
Staphylococcus aureus
(MRSA), and
Klebsiella pneumoniae
bacteria clinical isolates at a lower minimum inhibition concentration level (10–33 μM) as compared to its counterpart single-AMPs LL-37 and Renalexin (50–100 μM).
Key points
•
The hybrid antimicrobial peptide LL-37_Renalexin has been designed using a GS linker.
•
The peptide was expressed with the carrier proteins SmbP and CusF3H+.
•
The hybrid peptide shows antibacterial potency against clinical bacterial isolates. |
---|---|
ISSN: | 0175-7598 1432-0614 |
DOI: | 10.1007/s00253-023-12887-5 |